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A B S T R A C T
Background
Every day children and adults throughout the world die from acute community-acquired bacterial meningitis, particularly in low-
income countries. Survivors are at risk of deafness, epilepsy and neurological disabilities. Osmotic therapies have been proposed as
an adjunct to improve mortality and morbidity from bacterial meningitis. The theory is that they will attract extra-vascular fluid by
osmosis and thus reduce cerebral oedema by moving excess water from the brain into the blood. The intention is to thus reduce death
and improve neurological outcomes.
Objectives
To evaluate the effects on mortality, deafness and neurological disability of osmotic therapies added to antibiotics for acute bacterial
meningitis in children and adults.
Search methods
We searched CENTRAL 2012, Issue 11, MEDLINE (1950 to November week 3, 2012), EMBASE (1974 to November 2012),
CINAHL (1981 to November 2012), LILACS (1982 to November 2012) and registers of ongoing clinical trials (April 2012). We also
searched conference abstracts and contacted researchers in the field.
Selection criteria
Randomised controlled trials testing any osmotic therapy in adults or children with acute bacterial meningitis.
Data collection and analysis
Two review authors independently screened the search results and selected trials for inclusion. We collected data from each study for
mortality, deafness, seizures and neurological disabilities. Results are presented using risk ratios (RR) and 95% confidence intervals (CI)
and grouped according to whether the participants received steroids or not.
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Main results
Four trials were included comprising 1091 participants. All compared glycerol (a water-soluble sugar alcohol) with a control; in three
trials this was a placebo, and in one a small amount of 50% dextrose. Three trials included comparators of dexamethasone alone or
in combination with glycerol. As dexamethasone appeared to have no modifying effect, we aggregated results across arms where both
treatment and control groups received corticosteroids and where both treatment and control groups did not.
Compared to placebo, glycerol may have little or no effect on death in people with bacterial meningitis (RR 1.09, 95% confidence
interval (CI) 0.89 to 1.33, 1091 participants, four trials, low-quality evidence); or on death and neurological disability combined (RR
1.04, 95% CI 0.86 to 1.25).
Glycerol may have little or no effect on seizures during treatment for meningitis (RR 1.08, 95% CI 0.90 to 1.30, 909 participants,
three trials, low-quality evidence).
Glycerolmay reduce the risk of subsequent deafness (RR 0.60, 95% CI 0.38 to 0.93, 741 participants, four trials, low-quality evidence).
Authors’ conclusions
The only osmotic diuretic to have undergone randomised evaluation is glycerol. Data from trials to date have not demonstrated benefit
on death, but it may reduce deafness. Osmotic diuretics, including glycerol, should not be given to adults and children with bacterial
meningitis unless as part of carefully conducted randomised controlled trial.
P L A I N L A N G U A G E S U M M A R Y
Osmotic therapies added to antibiotics for acute bacterial meningitis
Meningitis is a condition where bacteria, fungi or viruses spread from the blood and infect the membranes and fluid that surround
the brain and spinal cord. All types of meningitis are very serious but acute bacterial meningitis has a rapid onset and is usually fatal
within hours to days without treatment. Signs and symptoms usually include high fever, severe headache, convulsions, coma and mental
confusion. Even with antibiotics the mortality rate is 10% to 15% in children with bacterial meningitis and 20% to 30% in adults
in high-income countries, rising to 50% in adults in low-income countries. Increased swelling of the brain caused by the infection is
thought to contribute to death and may lead to complications in survivors such as long-term brain damage, deafness, epilepsy and
learning difficulties in children. Bacterial meningitis is relatively rare in well-resourced settings but is more common in low-income
countries, particularly where the prevalence of HIV is high.
Osmotic therapies function by increasing the concentration of the blood and exerting an osmotic pressure across a semi-permeable
membrane (such as a cell wall or blood vessel lining in the brain) drawing water from the brain into the blood, thereby reducing pressure
in the brain. This is theoretically advantageous if brain swelling is causing a reduction in brain function. Osmotic therapies can reduce
brain swelling and potentially increase the rate of survival, or they could do harm. Glycerol is an osmotic treatment that was tested in
the four trials included in this review, with a total of 1091 participants. No other osmotic treatments have been tested in randomised
trials to date. This review detected no benefit from glycerol relating to death or neurological disabilities and one study in adults in
Malawi suggested it may do harm. Deafness was slightly less common in the osmotic group at follow-up but the effect was small. No
effect on epileptic seizures at follow-up was noted. Glycerol was not associated with any severe adverse effects. The number of trials
included was small and only two of the included studies tested a large number of participants. All trials were from differently resourced
healthcare settings and examined either adults or children.
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B A C K G R O U N D
Description of the condition
Community-acquired acute bacterial meningitis is a devastating
infection with associated rates of death and disability that have
changed little over the last 10 to 15 years. In high-income coun-
tries, 5% to30%of adult patients die, rising to 50% to60% in low-
income countries, despite highly effective antibiotics against the
causative pathogens (de Gans 2002; Nguyen 2007; Scarborough
2007). The high mortality is predominately seen in Streptococ-
cus pneumoniae (S. pneumoniae) infections; meningitis caused by
Neisseriameningitidis (N.meningitidis) carries a lowermortality. In
children, a wider range of pathogens are noted and the case fatality
rate is lower (Harnden 2006; Molyneux 2006; Pelkonen 2009;
Peltola 2009; Roine 2009). Nevertheless, some survivors develop
neurological problems that may be permanent. The most com-
mon meningitis sequelae are deafness, epilepsy and poor cognitive
development (Molyneux 2002; Nguyen 2007; van de Beek 2009),
thought to be caused by infection-induced inflammation, throm-
bosis and brain oedema (swelling). The outcome from bacterial
meningitis is influenced by the pathogen, the geographical area,
the patient’s access to health care and the quality of the healthcare
system. There are very few data on risk factors for poor outcomes
in low-income countries. However, anaemia and delayed presen-
tation to hospital are probably important (McCormick 2012;
Sudarsanam 2011). HIV may influence outcomes but the role of
the virus in pathogenesis is not yet clearly understood (Domingo
2009). High mortality rates, despite effective antibiotics, have led
investigators to try and minimise neurological inflammation with
adjunctive therapies.
Increasing understanding of the pathways of cerebral inflamma-
tion in meningitis has led several investigators to try treatments
that aim to reduce brain oedema and inflammation and improve
brain perfusion. The intervention most extensively tested in clin-
ical trials has been corticosteroids. A Cochrane Review (Brouwer
2010) shows a mortality benefit in adults in Europe with menin-
gitis due to S. pneumoniae and an overall reduction in deafness
in adults and children. A another systematic review, of individual
patient data from five randomised studies suggests that the effect
of dexamethasone on outcomes for bacterial meningitis in these
countries is limited to reducing the incidence of hearing loss in
survivors (van de Beek 2010). A long-held concern exists over ex-
cessive fluids contributing to brain oedema; a further Cochrane
Review suggests that judicious fluid resuscitation guided by the
clinical condition is appropriate tomaximise brain perfusion with-
out contributing to brain oedema (Maconochie 2011).
Description of the intervention
Osmotic therapies work by increasing the concentration of the
blood. They exert an osmotic pressure across a semi-permeable
membrane (such as a cell wall or blood vessel lining in the brain)
which draws water from the brain into the blood and reduces
pressure in the brain. This is theoretically advantageous if brain
swelling is causing reduction in brain function.
Osmotic therapies have long been used in acute brain trauma
(BTF 2000) and their use has been postulated in other forms of
acute brain injury, particularly stroke (Bereczki 2010; Yu 1992;
Yu 1993) and cerebral malaria (Namutangula 2007; Okoromah
2011). Mannitol and hypertonic saline are the most commonly
used osmotic therapies (Wakai 2008) but glycerol, sorbitol and
sodium lactate have also been investigated (Righetti 2005; Stoll
1998). Details of all these therapies have been reported in Table 1.
Glycerol has been studied in animals with meningitis, where no
effect was noted. Conclusions from these studies are limited by the
applicability of animal models of meningitis, where set doses of
pathogenic bacteria are introduced directly into the animal’s cen-
tral nervous system, to the complex host pathogen interactions in
human disease (Blaser 2010; Schmidt 1998). The excellent safety
profile of glycerol in previous studies (Righetti 2005), combined
with its low cost and easy administration and availability, has led
investigators to look for efficacy as adjuvant treatment in acute
bacterial meningitis in both adults and children, particularly in
low-income countries.
How the intervention might work
All osmotic therapies have slightly different and poorly understood
mechanisms of action. The osmotic drug’s mechanism of action
causes dehydration of central nervous system (CNS) cells, lower-
ing intracranial pressure (ICP). However this effect may only be
temporary and lead to a rebound phenomenon where cells subse-
quently draw in too much water, increasing the oedema.Mannitol
has this mechanism of action but acts primarily through a rhe-
ological action causing erythrocyte deformity through increases
in intravascular water, allowing increased tissue oxygenation in
the CNS. Mannitol produces a large diuresis through this effect,
which causes a reflex cerebral vaso-constriction, temporarily re-
ducing ICP. However, there is a significant risk of subsequent re-
bound raised ICP and mannitol is now used sparingly due to this
concern. The main mechanism of action of glycerol in humans
is unknown but there are some data to suggest that the addition
of glycerol in meningitis could potentially improve cerebral blood
flow and metabolism (Mathew 1972; Meyer 1972). Glycerol also
has a mild effect on serum osmolality (Singhi 2008).
Hypertonic saline and sodium lactate appear to have direct osmotic
actions on cells and they do not cause diuresis. These drugs may
therefore be better than mannitol in reducing ICP (Ichai 2009).
Osmotic diuretics such as mannitol and sorbitol could potentially
also have a clinical benefit in meningitis through reduction in ICP
but may risk volume depletion in the febrile patient. All osmotic
therapies ideally require an intact blood brain barrier to exert their
effects. Bacterial meningitis causes disruption of the barrier due
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to intense inflammation in the sub-arachnoid space and therefore
it cannot be assumed that osmotic therapies would be beneficial.
Table 1 gives details of all the properties of currently available
osmotic therapies.
Why it is important to do this review
To date, there have been a few placebo-controlled studies using
osmotic therapies in meningitis published in different settings in
children and adults. A systematic review and meta-analysis would
help to decide if these studies have demonstrated clinical bene-
fit either by improvement in mortality or long-term neurologi-
cal disabilities from the use of these treatments. This review will
therefore encompass all types of osmotic therapies to investigate
whether the principle of osmotic pressure change in the CNS is
of benefit in meningitis and will demonstrate whether osmotic
therapies should be recommended in principle, or if a particular
therapy should be recommended in the treatment of acute bacte-
rial meningitis.
O B J E C T I V E S
To evaluate the effects on death, deafness and neurological dis-
ability of osmotic therapies added to antibiotics for acute bacterial
meningitis in children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults and children diagnosed with acute community-acquired
bacterial meningitis, as defined by the trial authors, on the basis of
cerebral-spinal fluid (CSF) culture, white cell count, biochemical
composition and clinical presentation.
Types of interventions
Intervention: osmotic therapy, including at least one of the fol-
lowing: glycerol per oral (PO) administration, intravenous (IV)
hypertonic saline, sodium lactate and osmotic diuretics including
IV mannitol and sorbitol.
Control: standard IV therapy or matched placebo.
All participants receive broad-spectrum intravenous antibiotic
treatment.
Types of outcome measures
Primary outcomes
All-cause mortality.
Secondary outcomes
Mortality combinedwith residual neurological deficit at the end of
the follow-up period, including focal neurological deficit, epilepsy
and deafness. Deafness was defined as hearing loss at greater than
40 decibels bilaterally.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2012, Issue 11, part of The Cochrane Library,
www.thecochranelibrary.com (accessed 30 November 2012),
which contains the Acute Respiratory Infections Group’s Spe-
cialised Register, MEDLINE (1950 to November week 3, 2012),
EMBASE (1974 to November 2012), LILACS (1982 to Novem-
ber 2012) and CINAHL (1981 to November 2012).
We used the following search terms to search MEDLINE and
CENTRAL. We combined the MEDLINE search strategy with
the Cochrane highly sensitive search strategy for identifying
randomised trials in MEDLINE: sensitivity-maximising version
(2008 revision); Ovid format Lefebvre 2011. We adapted the
search strategy to search EMBASE (See Appendix 1), CINAHL
(see Appendix 2) and LILACS (see Appendix 3).
MEDLINE (Ovid)
1 exp Meningitis/
2 meningit*.tw.
3 1 or 2
4 Osmosis/
5 Osmotic Pressure/
6 exp Diuretics, Osmotic/
7 (osmos* or osmot* or osmol*).tw.
8 exp Sugar Alcohols/
9 glycer*.tw,nm.
10 1,2,3-propanetrio*.tw,nm.
11 mannitol*.tw,nm.
12 sorbit*.tw,nm.
13 Sodium Lactate/
14 (sodium adj2 lactat*).tw,nm.
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15 Saline Solution, Hypertonic/
16 (hypertonic adj2 saline*).tw,nm.
17 or/4-16
18 3 and 17
Searching other resources
We searched the following clinical trials registers in April 2012.
1. www.clinical trials.gov.
2. Meningitis research charities trial registers; the Meningitis
Research Foundation (www.meningitis.org).
3. Wellcome Trust and Medical Research Council trial
registers.
4. World Health Organization (WHO) trial registers.
One review author (EW) contacted the authors of all identified on-
going and published trials for details of other studies and contacts
for other researchers in the field, particularly for details of abstracts
presented at conferences not yet published in November 2010.
We handsearched relevant conference abstracts. We searched the
references of all identified trials for additional studies or informa-
tion.
Data collection and analysis
Selection of studies
One author (EW) screened all search results (title and abstract) and
selected relevant studies according to the review inclusion criteria.
Two authors (EW, KA) screened all selected studies by reading
the published full text to ensure each study met the inclusion
criteria. The same two authors then agreed which studies were
to be included in the review. We emailed trial authors to clarify
duplication and study numbers.
Data extraction and management
Two review authors (EW, KA) independently extracted all data
from the selected studies using a data extraction form. They dis-
cussed all trial data which was then included only when the data
matched that extracted by both review authors. We contacted one
trial author regarding duplication and we excluded one study from
the analysis as a result. No further discrepancies arose during data
extraction. We entered data for analysis using ReviewManager 5.1
software (RevMan 2011).
Assessment of risk of bias in included studies
The data extraction form included a ’Risk of bias’ collection tool.
Two review authors (EW, KA) independently judged the potential
risk of bias for each included study as low, uncertain or high for the
following parameters (Higgins 2011). Both review authors then
discussed and agreed the final judgements. One review author
(EW) synthesised these judgements into a standard ’Risk of bias’
table for each study. See Characteristics of included studies.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding.
4. Incomplete outcome data.
5. Selective reporting of outcome data.
6. Other identified areas of bias particular to that study (for
example, if the principal investigator was employed by the
pharmaceutical company manufacturing the drug under
investigation, or if the study is sponsored by a pharmaceutical
company).
Measures of treatment effect
The primary outcome of this review was binary and the studies
included were all RCTs, therefore we used risk ratio (RR) as the
most appropriate statistical tool to express the results of the treat-
ment effect in a meta-analysis. We displayed results as forest plots.
All included studies had outcomes defined by the trial authors
using standardised measurements. Hearing loss of greater than
40 dB was counted as significant where measured. If a formal
neurological score was used to define neurological disability this
was used.However, where only a descriptionwas given, a described
deficit that results in the participant not being able to work or
attend school was counted as significant. As the number of studies
was small we were not able to analyse mortality by continental
geographical area and resource setting as secondary outcomes, as
planned in the protocol.
Due to the small number of studies retrieved, we were not able
to group results for both primary and secondary outcomes by
the follow-up period: acute phase, less than three months since
inclusion in the study and longer-term up to one year of follow-
up.
Unit of analysis issues
We did not anticipate any cluster-randomised trials on this topic.
However, within the trials included a four parallel arm design was
employed. Data were separated into groups comparing the inter-
vention alone with placebo, and the intervention plus a second
intervention with the second intervention alone. These results are
expressed in Analysis 1.1 and Analysis 1.4.
Dealing with missing data
We found some relevant data to be missing from Kilpi 1995 and
Sankar 2007. We contacted the authors of both studies for clarifi-
cation but no further data were supplied. We proceeded with the
analysis despite this missing data.
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Assessment of heterogeneity
We intended to use the I2 statistic and to explore explanations for
heterogeneity by subgroup analysis as outlined in the protocol,
but data were insufficient.
Assessment of reporting biases
We assessed each study for reporting bias. Where it was suspected
that selected results had been presented, we contacted the authors
for clarification (see Dealing with missing data).
Data synthesis
We entered all extracted data into RevMan 2011 and performed
all analyses using this software.We expressed all results using forest
plots.We used a fixed-effectmodel for analysis and foundminimal
heterogeneity between the studies, so a random-effects model was
not required.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
All included studies found by the search strategy tested glycerol
compared to matched placebo, with some studies including a dex-
amethasone arm. One excluded study investigated mannitol. No
studies were found testing any other osmotic therapy or diuretic.
Results of the search
See Figure 1.
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Figure 1. Study screening flow diagram.
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We screened a total of 752 abstracts following the initial search in
November 2010. An update search in November 2012 identified
a further 35 records from the search of the electronic databases.
One ongoing trial is testing high-dose paracetamol and glycerol
compared with placebo in children with acute bacterial meningitis
aged 6 to 60 months in Malawi (Molyneux 2012).
Included studies
We included four trials with a total of 1091 participants meeting
the inclusion criteria (Ajdukiewicz 2011; Kilpi 1995; Peltola 2007;
Sankar 2007).One trial reported different outcomes from the same
trial in two separate publications (Sankar 2007; Singhi 2008).Data
from Sankar 2007 are presented in this analysis. Data from Singhi
2008 were not included in the analysis as that paper reported
osmolarity data exclusively and no mortality data were presented.
Participants
Three trials were conducted in children under 16 years (Kilpi
1995; Peltola 2007; Sankar 2007). The other trial was conducted
in adults and adolescents older than 14 years (Ajdukiewicz 2011).
Interventions
All included studies used oral glycerol as the primary intervention.
The potential mechanism of action of glycerol is detailed in Table
1. The three trials in children evaluated glycerol alone, dexam-
ethasone alone and glycerol combinedwith dexamethasone. These
studies used IV placebo to ’blind’ the dexamethasone treatment
group. No placebo for oral glycerol was used in Kilpi 1995 and
Sankar 2007, and Peltola 2007 used oral carboxymethylcellulose
as a placebo for glycerol.
The adult study used 50% dextrose as an oral placebo agent to
compare to glycerol diluted inwater or 50%dextrose (Ajdukiewicz
2011).
Location
Kilpi 1995 took place in Finland, Peltola 2007 in South America
(multiple sites), Sankar 2007 in India and Ajdukiewicz 2011 in
Malawi.
Outcomes
Death was the primary outcome in all included studies.
Excluded studies
We found that six studies, which each used ormentioned the use of
osmotic therapies, were not randomised controlled trials (RCTs)
and these were excluded (Figure 1).
Risk of bias in included studies
Allocation
The risk of bias was low for generation of allocation concealment
across all studies (Figure 2).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Blinding
The risk of bias was low for blinding across three studies. We
judged Kilpi 1995 at high risk of performance and detection bias,
as no details of any concealment were given, so we assumed that
the allocations were not blinded (Figure 2).
Incomplete outcome data
Two studies reported complete data and we judged them to have
a low risk of attrition bias (Ajdukiewicz 2011; Peltola 2007). Data
on two participants were missing from Kilpi 1995 and we judged
this study to have a high risk of attrition bias. Outcome data were
complete for Sankar 2007 but no data were given for important
outcomes including adverse effects or early cessation of treatment
and we assigned an unclear risk of attrition bias to this study.
Selective reporting
We judged Ajdukiewicz 2011 and Peltola 2007 to have a low
risk of reporting bias as all data appeared to be presented clearly
and completely. Kilpi 1995 presented selected data as there was
significant attrition bias, so we judged it to have a high risk of
reporting bias. We judged Sankar 2007 to have an unclear risk of
reporting bias as no adverse effects nor time of stopping treatment
were presented.
Other potential sources of bias
No trials were sponsored by pharmaceutical companies, nor were
the authors declared to have significant conflicts of interest. Peltola
2007 was partly funded by a pharmaceutical company but this
supplied the dexamethasone for the trial and not the glycerol, sowe
did not judge this to have a significant bias effect on this analysis.
Effects of interventions
See: Summary of findings for the main comparison Glycerol
for acute bacterial meningitis
Four trials were included, all evaluating glycerol. Three of the trials
had four arms, which also compared glycerol plus dexamethasone
with dexamethasone alone.We carried out the initial analysis com-
paring participants who received glycerol or placebo only, labelled
’no steroids’, and carried out a subgroup analysis with the remain-
ing trial participants who received either glycerol plus dexametha-
sone or dexamethasone plus placebo, labelled ’with steroids’. All
trial participants received the antibiotic ceftriaxone, so no antibi-
otic subgroup analysis was necessary. Due to the small number of
included studies, a subgroup analysis of purely paediatric data was
not required.
Glycerol
All-cause death
In the adult study, there were more deaths in the glycerol group
and this led to the study being stopped by the data monitoring
committee (risk ratio (RR) 1.30, 95% confidence interval (CI)
1.04 to 1.62) (Ajdukiewicz 2011). None of the other studies de-
tected harm with glycerol and the meta-analysis did not detect an
effect on mortality (RR 1.09, 95% CI 0.89 to 1.33, 1091 partic-
ipants, four trials, Analysis 1.1). The stratified analysis found no
significant difference whether dexamethasone was administered or
not.
Deaths plus long-term disability
Overall, 21 cases of neurological disability were reported in the
glycerol group and 25 cases in the placebo group. All-cause mor-
tality was combined with neurological disability and no effect of
glycerol was detected (RR 1.04, 95% CI 0.86 to 1.25, 1091 par-
ticipants, four trials, Analysis 1.2) with no pattern evidence on
stratification by whether steroids were received or not.
Seizures, convulsions and epilepsy
Convulsions on admission and during treatment were reported
in all studies but none of the studies reported data for persis-
tent epileptic seizures post discharge. In the adult study, risk of
seizures was higher with glycerol (RR 1.62, 95% CI 1.18 to 2.23)
(Ajdukiewicz 2011). However, this was not found in the other
studies and themeta-analysis did not detect a difference (RR 1.08.
95% CI 0.90 to 1.30, 909 participants, three trials (Analysis 1.3).
Deafness
Fewer surviving participants given glycerol were reported as deaf
at four to eight weeks of follow-up compared to placebo (RR 0.60,
95% CI 0.38 to 0.93, four trials, 741 participants, low-quality
evidence (Analysis 1.4).
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Adverse effects
Neither glycerol nor dexamethasone were associated with signifi-
cant adverse effects in the included studies but systematic record-
ing of adverse events was not reported. Common adverse effects
were nausea and vomiting, with small numbers of cases of gas-
tro-intestinal bleeding reported in Sankar 2007, Kilpi 1995 and
Peltola 2007, all in the dexamethasone groups.
D I S C U S S I O N
Summary of main results
We only identified four trials evaluating glycerol in acute bacterial
meningitis. Other osmotic diuretics, such as mannitol and hyper-
tonic saline, have not yet been tested.
Glycerol was tested in adults and children with acute bacterial
meningitis in a variety of different clinical settings and in three of
the four included trials, glycerol was evaluated in a complex trial
design including dexamethasone. The review and meta-analysis
did not detect an overall effect of glycerol on mortality from acute
bacterial meningitis in children and adults. However, in the single
trial in adults, glycerol was associated with increased mortality.
The quality of the evidence using GRADE criteria (GRADEpro
2008) was low (Summary of findings for the main comparison).
This meta-analysis of low-quality evidence suggests that glyc-
erol may reduce hearing loss (Summary of findings for the main
comparison).
The small numbers seen overall in the paediatric studies are not
sufficient to fully exclude the impact of dexamethasone, particu-
larly on neurological disabilities and deafness in children, as this
has been shown to be effective elsewhere (van de Beek 2010).
The results of the ongoing study of glycerol in children in Malawi
(Molyneux 2012) will add to the data when we update our review
and provide larger numbers for more rigorous analysis.
The overall numbers in this analysis were small and there is a
significant degree of bias present in the two smaller studies. The
weighting of the analysis is mainly on Ajdukiewicz 20111 and
Peltola 2007, two large studies which were both well conducted
but limited in their population demographics and follow-up data.
Data from Peltola 2007 have been subject to systematic reviews in-
vestigating the effect of dexamethasone, and somemethodological
concerns were raised regarding the randomisation schedule (van
de Beek 2010).
Each study was undertaken in a very different environment and
the population for each has its own particular issues. The HIV
prevalence in Ajdukiewicz 2011 was 83.5% and the impact of this
on mortality and other outcomes has not been measured and may
be significant. This study was conducted in a severely resource-
limited environment in Malawi, with no access to advanced re-
suscitation or intensive care units (ICUs) (UNDP 2009). All the
other studies were carried out in hospitals with ICUs and pae-
diatric specialist teams, which is not necessarily representative of
most hospitals in low-income countries and this may introduce
a degree of confounding, particularly regarding lower mortality
rates in children.
The study by Peltola 2007 was conducted across multiple sites
and excluded participants who had received parenteral antibiotics
but not oral antibiotics before the first dose of glycerol and/or
dexamethasone. The authors of this study do not include these
data in the analysis, so it is unclear if prior antibiotic treatment
had an effect on outcomes, particularly deafness.
The doses and duration of glycerol used varied across the included
studies, introducing further inconsistencies between the studies,
outlined in Table 2.We were unable to control for this in the anal-
ysis, which may have introduced further heterogeneity (Brouwer
2011; Saez-Llorens 2007). Prolonged use of osmotic agents, such
as the four-day courses of glycerol used in Ajdukiewicz 2011, have
been suggested to be harmful. Peltola 2007 and Sankar 2007 both
utilised two-day courses due to this concern. However, the ma-
jority of seizures and deaths in Ajdukiewicz 2011 occurred in the
first two days, and therefore an association between mortality and
glycerol duration is unlikely.
Different agents were used as placebo comparators across the stud-
ies. Ajdukiewicz 2011 used 50%dextrose, Peltola 2007 and Sankar
2007 used carboxymethylcellulose and Kilpi 1995 did not use a
placebo agent. It may be argued that the placebo agents used were
not wholly inert and may exert an independent osmotic action.
All authors designed control agents that had a similar taste and
texture to glycerol for concealment purposes, and it is untested if
any of the substances used exerted an independent osmotic action.
However, the highermortality in Ajdukiewicz 2011 in the glycerol
group suggests glycerol had an action beyond any osmotic effect
exerted by the dextrose placebo, particularly as the glycerol was
diluted in dextrose for some participants (Brouwer 2011).
The reduction in hearing loss observed suggests that glycerol may
be acting to reduce oedema or improve cerebral blood flow in
particular areas of the brain, either the nucleus or length of the
vestibular-cochlear nerve (which is encased in a bony canal). There
is some evidence to suggest that glycerol is required for bacterial
metabolic pathways in the central nervous system (CNS) (Mahdi
2012). Genetic susceptibility to hearing loss following meningitis
has been suggested and the presence of glycerol may attenuate the
production of free radicals that may affect CNS damage leading to
hearing loss (vanWell 2012).We selected greater than 40 dB as the
cut-off for hearing loss to capture all clinically significant deficits;
the effect of glycerol onmore severe hearing loss was not evaluated.
Currently there are no clear data showing the mechanistic effects
of glycerol on either hearing or mortality in humans and more
research is needed. Experimental animal work has shown no effect
of glycerol in a bacterialmeningitismodel (Blaser 2010). The cause
of increased mortality with glycerol in adults is unclear but may
relate to enhanced virulence of pneumococci in the CNS in the
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presence of glycerol (Mahdi 2012).
The use of dexamethasone did not have any impact on the out-
comes studied when used with or without glycerol. Other larger
reviews have found an impact of dexamethasone in reduction of
hearing loss in children with meningitis (van de Beek 2010). The
data in this review are much smaller than were analysed in the
other studies and therefore no conclusion as to the utility of dex-
amethasone in meningitis can be drawn from this review.
Overall completeness and applicability of
evidence
This is the first Cochrane Review examining the evidence for the
use of osmotic therapies in acute bacterial meningitis. To date the
evidence is incomplete and therefore we cannot recommend the
use of glycerol in meningitis. Data from further ongoing stud-
ies are required, particularly in children to assess the impact of
glycerol on meningitis-induced hearing loss. There is no evidence
testing any other osmotic therapy apart from glycerol for menin-
gitis and therefore the overall use of osmotic therapies in acute
bacterial meningitis cannot be recommended. The high-quality
evidence from Ajdukiewicz 2011 demonstrates harm from glyc-
erol in adults with bacterial meningitis in Malawi and no further
testing or clinical use of glycerol in adults is currently warranted.
Quality of the evidence
We have assessed the quality of evidence provided by this review
using the GRADE methods, and this is presented in Summary
of findings for the main comparison. The evidence is generally
considered to be of low or very low quality, which indicates that
further research is very likely to change these estimates of effect.
The main reason for downgrading quality was the small size of the
trials, and the low number of events and substantial differences
between the locations, sizes and patient populations studied in the
included studies. Much larger trials would be necessary to prove
or exclude significant benefits or harms.
We also downgraded the evidence for mortality and seizures for
inconsistency. The single trial in adults (Ajdukiewicz 2011) was
stopped early due to small but statistically significant harm, while
the three trials in children have so far not demonstrated statistically
significant effects.
Potential biases in the review process
Dr Katherine Ajdukiewicz is an author of this review and was the
principal investigator for one of the studies included in this review.
To minimise bias she did not extract any data from her study to
include in the analysis or perform any of the analysis.
Agreements and disagreements with other
studies or reviews
There are no current systematic reviews examining glycerol or
other osmotic agents for use in acute bacterial meningitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence to support the use of glycerol as adjunctive
treatment for acute bacterial meningitis. Glycerolmay have a small
beneficial effect on reducing deafness in surviving children but
further data are needed and the quality of the overall evidence
is low. When the results of the paediatric study in Malawi are
available (Molyneux 2012) they will be added to the analysis.
Implications for research
Trials testing other osmotic interventions in acute bacterial menin-
gitis may be considered, particularly in children.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajdukiewicz 2011
Methods Randomised controlled trial
Participants Adults with bacterial meningitis (clinical suspicion of meningitis plus CSF evidence of
infection: > 100 white cells/mm3, predominately neutrophils, a positive gram stain or
cloudy CSF)
Interventions Oral glycerol 75 mg in 135 ml
Oral glucose 50% solution 135 ml
Outcomes Primary outcome: mortality
Secondary outcomes: epilepsy, deafness, residual neurological deficit
Notes Placebo is not potentially completely inactive and 50% glucose may exert a neurological
effect in meningitis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation number list in blocks of 12 was pro-
duced by an independent statistician using Stata version
9.0”
Allocation concealment (selection bias) Low risk “Numbers and allocation were placed into sealed en-
velopes. Envelopes were opened sequentially by an inde-
pendent person not involved in the clinical care or assess-
ment of trial participants”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Triple blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis, all patients included in the
analysis
Selective reporting (reporting bias) Low risk None apparent
Other bias Low risk No other biases apparent
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Kilpi 1995
Methods Randomised controlled trial with 4 arms
Participants Children from 3 months to 15 years of age with bacterial meningitis (CSF culture
positive; CSF leucocytes > 100/mm2; positive blood culture in a patient with signs and
symptoms of bacterial meningitis)
Interventions Glycerol 4.5 g/kg to a maximum 180 g/day divided into 3 doses/24 hours. Increased by
50% for dose 1 and decreased by 50% for dose 2. No details of placebo given. 3 days
treatment given
Dexamethasone 1.5 mg/kg od IV divided into 3 doses/24 hours. 50% dose adjustments
as per glycerol also used. 3 days treatment given
4 groups used, glycerol, glycerol + dexamethasone, dexamethasone and ’neither’
Outcomes Primary outcome: mortality
Secondary outcomes: epilepsy, deafness, residual neurological deficit
Notes No details given if any placebo agent was used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer generated list of random ther-
apy assignments was kept at the children’s
hospital”
Allocation concealment (selection bias) Low risk “The next adjunctive treatment regimenwas
obtainable by telephone 24 hours a day”
It is not clear if this person giving the assign-
ments was part of the study team or inde-
pendent
Blinding (performance bias and detection
bias)
All outcomes
High risk No details of blinding are given, so we as-
sumed that the study was unblinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 134 children enrolled, 12 excluded, 122 in
the final series but 120only analysed.Details
of the missing data are not present in the
text
Selective reporting (reporting bias) High risk No details of the missing data given, so it is
not clear if selective cases only are presented
Other bias Unclear risk Groups not completely matched, increased
females in the dexamethasone group and in-
creased meningitis due to S. pneumoniae in
the control group
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Peltola 2007
Methods Randomised controlled trial with 4 arms, multicentre in South America
Participants Children aged 2 months to 16 years with bacterial meningitis (CSF culture positive,
“characteristic CSF findings” with a positive blood culture or CSF positive with latex
antigen test; symptoms and signs of bacterial meningitis with at least 3 of the following:
CSF white cell count > 1000 cells/mm3, CSF glucose < 40 mg/dL, CSF protein > 40
mg/dL, blood white cell count >15000 cells/mm3
Interventions Glycerol 1.5 g/kg in an 85% solution divided into 3 doses/24 hours. 2 days treatment
given. Placebo saline plus carboxy methylcellulose. Doses and volumes of placebo not
given in the paper
Dexamethasone 0.15 mg/kg od IV divided into 3 doses/24 hours. 2 days treatment given
4 groups used, GLY + placebo, GLY + Dex, Dex + placebo and placebo + placebo
Outcomes Primary mortality. No secondary mortality at the end of follow up given
Secondary outcomes: epilepsy, deafness and residual neurological deficit
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Stratified block randomisation took place
in blocks of 20”
Allocation concealment (selection bias) Low risk “All treatment kits were packaged accord-
ing to the randomisation lists in Santiago,
Chile. Saline and carboxymethylcellulose
were the placebo preparations for dexam-
ethasone and glycerol, respectively
The agents were provided in identical am-
poules or bottles and were labelled only
with a study code”
Blinding (performance bias and detection
bias)
All outcomes
Low risk The placebos and blinding are described
above
Incomplete outcome data (attrition bias)
All outcomes
Low risk None identified
Selective reporting (reporting bias) Low risk No missing data identified
Other bias Unclear risk Drugs were supplied by GlaxoSmithK-
line and Famacia Ahumada. GSK partially
funded the study
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Sankar 2007
Methods Randomised controlled trial. Single centre
Participants Children aged 2 months to 12 years with bacterial meningitis (positive CSF culture or
CSF latex agglutination positive, or CSF cytology with a suggestive biochemical profile
with fever and signs of CNS involvement)
Interventions Glycerol 1.5 g/kg IV or PO 6-hourly. Placebo carboxymethyl cellulose 2% solution IV.
Total dose of placebo not given just documented “matched”. Dexamethasone 0.15 mg/
kg 6-hourly. Duration of treatment not given in the text
Outcomes Primary mortality. No secondary mortality at the end of follow-up given
Secondary outcomes: epilepsy, deafness and residual neurological deficit
Notes This study was published twice, with a preliminary analysis of the osmotic effects pub-
lished as Singhi 2008. Study funding, the source of drugs or co-infection documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list prepared with simple
random numbers table
Allocation concealment (selection bias) Low risk Serially numbered, sealed packets prepared,
kept readily available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Clinicians and patients blinded. It is not
clear from the text if the investigators were
fully blinded but the packets were prepared
by a separate person from the investigating
team
CSF: cerebral spinal fluid
CNS: central nervous system
Dex: dexamethasone
GLY: glycerol
IV: intravenous
od: once daily
PO: per-oral
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alimarante 1995 Case series of mannitol used for bacterial meningitis. No randomisation or placebo use documented
Herson 1977 Not a randomised controlled trial. Glycerol use discussed
Pecco 1991 Literature review and documented personal experience of the use of mannitol in meningitis
Pelegrin 2012 Retrospective cohort study examining patients with bacterial meningitis 1987 to 2009 who were treated with
dexamethasone, mannitol and phenytoin. No data were collected prospectively and participants were not ran-
domised to receive any of the interventions
Peltola 2010 This is not a new trial, but is a specific analysis of Peltola 2007 trial looking at deafness in more detail
Singhi 2004 Review article not randomised controlled trial
Singhi 2007 Letter in response to the journal editorial summary of the trial Peltola 2007
Singhi 2008 Duplicated trial of Sankar 2007. This was a subset of the data published in Sankar 2007, an included study.
Singhi 2008 reports osmolality effects of glycerol rather than mortality outcome
Urciuoli 1963 Mannitol tested for neurosurgical infections and not acute bacterial meningitis. Not a randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Molyneux 2012
Trial name or title Glycerol and high dose paracetamol for paediatric meningitis
Methods Randomised controlled trial with 4 arms
Participants Children under 12 years with acute bacterial meningitis
Interventions Oral glycerol and oral paracetamol
Outcomes Death, hearing loss, neurological disability, cognitive ability
Starting date 2010
Contact information Professor Elizabeth Molyneux, Queen Elizabeth Central Hospital, Blantyre, Malawi
Notes Trial due to complete 2012
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D A T A A N D A N A L Y S E S
Comparison 1. Glycerol versus no osmotic diuretic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 1091 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.89, 1.33]
1.1 No steroids 4 672 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.89, 1.36]
1.2 With steroids 3 419 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.60, 1.74]
2 Death and neurological disability 4 1091 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.86, 1.25]
2.1 No steroids 4 672 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.87, 1.31]
2.2 With steroids 3 419 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.62, 1.46]
3 Seizures 3 909 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.90, 1.30]
3.1 No steroids 3 574 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.91, 1.43]
3.2 With steroids 2 335 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.70, 1.33]
4 Hearing loss 4 741 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.38, 0.93]
4.1 No steroids 3 391 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 0.98]
4.2 With steroids 3 350 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.32, 1.35]
Analysis 1.1. Comparison 1 Glycerol versus no osmotic diuretic, Outcome 1 Death.
Review: Osmotic therapies added to antibiotics for acute bacterial meningitis
Comparison: 1 Glycerol versus no osmotic diuretic
Outcome: 1 Death
Study or subgroup Glycerol Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No steroids
Kilpi 1995 0/30 0/26 0.0 [ 0.0, 0.0 ]
Sankar 2007 1/13 1/13 1.00 [ 0.07, 14.34 ]
Peltola 2007 17/166 26/163 0.64 [ 0.36, 1.14 ]
Ajdukiewicz 2011 86/136 61/125 1.30 [ 1.04, 1.62 ]
Subtotal (95% CI) 345 327 1.10 [ 0.89, 1.36 ]
Total events: 104 (Glycerol), 88 (Placebo)
Heterogeneity: Chi2 = 5.49, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.91 (P = 0.36)
2 With steroids
Kilpi 1995 2/31 0/31 5.00 [ 0.25, 100.08 ]
0.005 0.1 1 10 200
Favours glycerol Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Glycerol Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Peltola 2007 20/159 23/166 0.91 [ 0.52, 1.59 ]
Sankar 2007 1/20 0/12 1.86 [ 0.08, 42.27 ]
Subtotal (95% CI) 210 209 1.02 [ 0.60, 1.74 ]
Total events: 23 (Glycerol), 23 (Placebo)
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 555 536 1.09 [ 0.89, 1.33 ]
Total events: 127 (Glycerol), 111 (Placebo)
Heterogeneity: Chi2 = 7.22, df = 5 (P = 0.21); I2 =31%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.005 0.1 1 10 200
Favours glycerol Favours placebo
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Analysis 1.2. Comparison 1 Glycerol versus no osmotic diuretic, Outcome 2 Death and neurological
disability.
Review: Osmotic therapies added to antibiotics for acute bacterial meningitis
Comparison: 1 Glycerol versus no osmotic diuretic
Outcome: 2 Death and neurological disability
Study or subgroup Glycerol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No steroids
Ajdukiewicz 2011 86/136 61/125 45.6 % 1.30 [ 1.04, 1.62 ]
Kilpi 1995 0/30 2/26 1.9 % 0.17 [ 0.01, 3.47 ]
Peltola 2007 24/166 35/163 25.3 % 0.67 [ 0.42, 1.08 ]
Sankar 2007 4/13 2/13 1.4 % 2.00 [ 0.44, 9.08 ]
Subtotal (95% CI) 345 327 74.3 % 1.07 [ 0.87, 1.31 ]
Total events: 114 (Glycerol), 100 (Placebo)
Heterogeneity: Chi2 = 8.68, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 0.64 (P = 0.52)
2 With steroids
Kilpi 1995 2/31 3/31 2.2 % 0.67 [ 0.12, 3.72 ]
Peltola 2007 28/159 33/166 23.2 % 0.89 [ 0.56, 1.40 ]
Sankar 2007 4/20 0/12 0.4 % 5.57 [ 0.33, 95.23 ]
Subtotal (95% CI) 210 209 25.7 % 0.95 [ 0.62, 1.46 ]
Total events: 34 (Glycerol), 36 (Placebo)
Heterogeneity: Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 555 536 100.0 % 1.04 [ 0.86, 1.25 ]
Total events: 148 (Glycerol), 136 (Placebo)
Heterogeneity: Chi2 = 11.28, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours glycerol Favours control
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Analysis 1.3. Comparison 1 Glycerol versus no osmotic diuretic, Outcome 3 Seizures.
Review: Osmotic therapies added to antibiotics for acute bacterial meningitis
Comparison: 1 Glycerol versus no osmotic diuretic
Outcome: 3 Seizures
Study or subgroup Glycerol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No steroids
Ajdukiewicz 2011 64/129 37/121 26.0 % 1.62 [ 1.18, 2.23 ]
Peltola 2007 42/148 50/150 33.8 % 0.85 [ 0.60, 1.20 ]
Sankar 2007 4/13 7/13 4.8 % 0.57 [ 0.22, 1.49 ]
Subtotal (95% CI) 290 284 64.6 % 1.14 [ 0.91, 1.43 ]
Total events: 110 (Glycerol), 94 (Placebo)
Heterogeneity: Chi2 = 9.48, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.16 (P = 0.25)
2 With steroids
Peltola 2007 43/148 48/155 32.0 % 0.94 [ 0.66, 1.32 ]
Sankar 2007 8/20 4/12 3.4 % 1.20 [ 0.46, 3.15 ]
Subtotal (95% CI) 168 167 35.4 % 0.96 [ 0.70, 1.33 ]
Total events: 51 (Glycerol), 52 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 458 451 100.0 % 1.08 [ 0.90, 1.30 ]
Total events: 161 (Glycerol), 146 (Placebo)
Heterogeneity: Chi2 = 10.47, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
Favours glycerol Favours placebo
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Analysis 1.4. Comparison 1 Glycerol versus no osmotic diuretic, Outcome 4 Hearing loss.
Review: Osmotic therapies added to antibiotics for acute bacterial meningitis
Comparison: 1 Glycerol versus no osmotic diuretic
Outcome: 4 Hearing loss
Study or subgroup Glycerol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No steroids
Kilpi 1995 1/28 6/24 13.5 % 0.14 [ 0.02, 1.10 ]
Peltola 2007 12/136 12/131 25.6 % 0.96 [ 0.45, 2.07 ]
Ajdukiewicz 2011 4/31 14/41 25.3 % 0.38 [ 0.14, 1.04 ]
Subtotal (95% CI) 195 196 64.4 % 0.56 [ 0.32, 0.98 ]
Total events: 17 (Glycerol), 32 (Placebo)
Heterogeneity: Chi2 = 4.23, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 2.03 (P = 0.042)
2 With steroids
Kilpi 1995 0/31 3/30 7.4 % 0.14 [ 0.01, 2.57 ]
Sankar 2007 2/13 3/9 7.4 % 0.46 [ 0.10, 2.23 ]
Peltola 2007 9/132 10/135 20.7 % 0.92 [ 0.39, 2.19 ]
Subtotal (95% CI) 176 174 35.6 % 0.66 [ 0.32, 1.35 ]
Total events: 11 (Glycerol), 16 (Placebo)
Heterogeneity: Chi2 = 1.86, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.26)
Total (95% CI) 371 370 100.0 % 0.60 [ 0.38, 0.93 ]
Total events: 28 (Glycerol), 48 (Placebo)
Heterogeneity: Chi2 = 6.20, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours glycerol Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Available osmotic therapies
Drug Class Mechanism of action Dose range and route Studied/used in
Glycerol Sugar alcohol Probably osmosis plus pos-
sible vascular and metabolic
benefit
IV 5% to 10% solution or
50 g
PO 1.5 g/kg
Meningitis (Peltola 2007),
stroke (Righetti 2005)
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Table 1. Available osmotic therapies (Continued)
Mannitol Sugar alcohol Osmotic diuretic IV 20% solution
1 ml/kg to 10 ml/kg or 1 g/
kg
Brain trauma (Wakai 2008)
, cerebral malaria (
Namutangula 2007), stroke
(Bereczki 2010)
Sorbitol Sugar alcohol Osmotic diuretic (weak) PO, IV Experimental brain perfu-
sion, stroke
Hypertonic
saline
Hypertonic solutions Osmosis IV Brain trauma (Choi 2005),
stroke (Schwarz 2002)
Sodium
lactate
Hydroxy acids Osmosis (weak) IV Brain trauma (Ichai 2009)
IV: intravenous
PO: per oral
Table 2. Comparison of included study interventions
Name of study Population Intervention and
dose
Control used Treatment
duration
Study arms
Kilpi 1995 Children in Finland Glycerol (gly) PO 4.
5 g/kg max 180 g/
24 hrs in 3 divided
doses
Dexamethasone
(dex) 1.5mg/kgmax
60 mg/day
No oral placebo
IV saline
3 days 4 arms IV dex + gly,
PO gly, IV dex, and
neither treatment
Sankar 2007 Children in India Glycerol PO 1.5 g/
kg 3 x daily
Dex 0.15 mg/kg 3 x
daily
Oral car-
boxymethylcellulose
2%
IV saline
Not detailed 4 arms placebo PO
and IV, IV dex + PO
gly, IV placebo + PO
gly, IV dex + PO
placebo
Peltola 2007 Children in South
America
Glycerol PO 1.5 g/
kg 3 x daily
Dex 0.15 mg/kg 3 x
daily
Oral car-
boxymethylcellulose
2%
IV saline
2 days 4 arms placebo PO
and IV, IV dex + PO
gly, IV placebo + PO
gly, IV dex + PO
placebo
Ajdukiewicz 2011 Adults in Malawi,
Southern Africa
Glycerol PO 75 mg
4 x daily diluted in
water or 50% dex-
Oral 50% dextrose
solution
4 days PO gly versus PO
50% dextrose
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Table 2. Comparison of included study interventions (Continued)
trose solution
IV: intravenous
PO: per oral
gly: glycerol
dex: dexamethasone
A P P E N D I C E S
Appendix 1. EMBASE search strategy
Embase.com
#20 #16 AND #19
#19 #17 OR #18
#18 random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR assign*:
ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR ((doubl* OR singl*) NEAR/2 (blind* OR mask*)):ab,ti
#17 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#16 #3 AND #15
#15 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#14 (hypertonic NEAR/2 saline):ab,ti
#13 ’sodium chloride’/de
#12 (lactat* NEAR/2 sodium):ab,ti
#11 ’lactate sodium’/de
#10 sorbit*:ab,ti
#9 mannitol*:ab,ti
#8 ’1,2,3-propanetriol’:ab,ti OR propanetrio*:ab,ti
#7 glycer*:ab,ti
#6 ’sugar alcohol’/exp
#5 osmotic*:ab,ti
#4 ’osmotic diuretic agent’/exp
#3 #1 OR #2
#2 meningit*:ab,ti
#1 ’meningitis’/exp
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Appendix 2. CINAHL search strategy
CINAHL (Ebsco)
S12 S3 and S11
S11 S4 or S5 or S6 or S7 or S8 or S9 or S10
S10 TI hypertonic N2 saline or AB hypertonic N2 saline
S9 (MH “Saline Solution, Hypertonic”)
S8 TI sodium N2 lactat* or AB sodium N2 lactat*
S7 TI ( glycerol* or 1,2,3-propanetriol or propanetriol* or mannitol* or sorbit* ) or AB ( glycerol* or 1,2,3-propanetriol or propanetriol*
or mannitol* or sorbit* )
S6 AB sugar alcohol* or TI sugar alcohol*
S5 (MH “Sugar Alcohols+”)
S4 TI osmotic* or AB osmotic*
S3 S1 or S2
S2 TI meningit* or AB meningit*
S1 (MH “Meningitis+”)
Appendix 3. LILACS search strategy
LILACS (BIREME)
> Search > MH:Meningitis OR Meningite OR MH:C10.228.228.507$ OR C10.228.566$ OR MH:C01 252.200$ OR
C10.228.228.180.500$ OR meningit$ AND MH:“Diuretics, Osmotic” OR “Diuréticos Osmóticos” OR “Diuréticos Osmóticos”
OR “Osmotic Diuretics” OR MH:D27.505.696.560.500.453$ OR osmot$ OR osmos$ OR osmol$ OR MH:“Sugar Alcohols” OR
“Alcoholes del Azúcar” OR “Álcoois de Açúcar” OR MH:D02.033.800$ OR MH:D09.853$ OR “sugar alcohols” OR glycer$ OR
“1,2,3-propanetriol” OR mannitol$ OR sorbit$ OR MH:“Sodium Lactate” OR “Lactato de Sodio” OR “Lactato de Sódio” OR MH:
D02.241.511.459.500$ OR “sodium lactate” ORMH:“Saline Solution, Hypertonic” OR “Solución Salina Hipertónica” OR “Solução
Salina Hipertônica” OR “Hypertonic Saline Solution” OR “Sodium Chloride Solution, Hypertonic” OR “Hypertonic Solution, Saline”
OR “SoluciónHipertónica de Cloruro de Sodio” OR “SoluçãoHipertônica de Cloreto de Sódio” OR “hypertonic saline” > clinical˙trials
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